-
News | 2017.11.14
130 years ago, the Institut Pasteur was under construction
On June 4, 1887, the Institut Pasteur was created following the success of the rabies vaccine developed by Louis Pasteur – and thanks to the generous support of countless donors. Just set up as an institution with official charitable status, the building work began straight away."This is the start of post-exposure rabies prophylaxis. (...) A rabies vaccine center should be set up," declared Louis...
-
Article | 2020.08.20
Industrial property
The Institut Pasteur is in the world's top 10 list for US and European patents granted in the field of life sciences for the period 2010-2014.
-
Document de presse | 2021.03.26
COVID-19: analysis of the sensitivity of the UK (B.1.1.7) and South African (B.1.351) variants to SARS-CoV-2 neutralizing antibodies
The B.1.1.7 and B.1.351 variants of SARS-CoV-2 were first detected in the UK and South Africa respectively, and have since spread to many other countries. Scientists from the Institut Pasteur joined forces with Orléans Regional Hospital, Tours University Hospital, Créteil Intercommunal Hospital, Strasbourg University Hospital and Georges Pompidou European Hospital to study the sensitivity of...
-
News | 2020.02.05
Meningococci: an example of genomics used as an epidemiological tool
By examining vaccine coverage of invasive meningococcal infections in conjunction with genomic and pathophysiological analyses, it was possible to detect a new genotype in meningococcal serogroup W and characterize the emergence of the resulting bacterial strain. This combined approach has been a useful decision-making tool in implementing measures to control invasive meningococcal infections in...
-
News | 2022.04.14
Monoclonal antibody SPK001: potent and broad neutralization activity across all SARS-CoV-2 variants of concern
SPK001, the monoclonal antibody developed by SpikImm, a biotech company founded by the Institut Pasteur and Truffle Capital, has demonstrated a potent and broad neutralization activity across all SARS-CoV-2 variants of concern, including omicron (BA.1 and BA.2). Originally developed in the Humoral Immunology lab headed by Dr Hugo Mouquet at the Institut Pasteur (joint research unit Inserm),...
-
Article | 2025.08.19
Environmental transitions and health - Pasteur 2030
Climate change favors the emergence of infectious diseases. Institut Pasteur deploys strategies integrating human, animal and environmental health to reduce these risks.
-
Document de presse | 2016.03.03
Antibodies capable of eliminating HIV-infected cells
Researchers from the Institut Pasteur, CNRS and Vaccine Research Institute (ANRS/Inserm) have recently shown that some effective antibodies recognize cells infected by the human immunodeficiency virus (HIV) and trigger their destruction by the immune system. This discovery sheds new light on the mechanism of action of these specific antibodies, which are currently undergoing clinical trials....
-
News | 2020.07.06
Hepatitis B: natural controllers shed light on immunity mechanisms
Infections in humans caused by the hepatitis B virus (HBV) represent a major public health problem. Despite the availability of effective protective vaccines, more than 250 million individuals worldwide are chronically infected according to WHO estimates. HBV infection is associated with cirrhosis, liver failure and hepatocellular carcinoma, responsible for approximately a million deaths every...
-
Document de presse | 2021.03.07
COVID-19: neutralizing immune response lasts longer in women than in men
As part of the SEROCoV-HUS study, teams from Strasbourg University Hospital and the Institut Pasteur monitored 308 hospital staff who had previously contracted a mild form of SARS-CoV-2. The scientists demonstrated that neutralizing antibodies could be detected in 84% of them up to 6 months after infection, but that the level fell more quickly in men than in women. These results seem to suggest...
-
Document de presse | 2022.12.13
Epidemics, pandemics: a never-ending story? – a look back at the conference held on December 7, 2022
In connection with the bicentenary of Louis Pasteur’s birth, a conference entitled "Epidemics, pandemics: a never-ending story?" was held on Wednesday December 7 at the Institut Pasteur under the high patronage of the French President, Emmanuel Macron. The conference marked the end of a year of events highlighting not only the importance of research in tackling infectious diseases, but also the...